PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium

LAGUNA HILLS, Calif., Nov. 16, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that data will be presented in four separate poster presentations at the 2022 San Antonio Breast...

Click to view original post